Salt and crystal form of egfr inhibitor, and composition and use thereof
US-2024352053-A1 · Oct 24, 2024 · US
US2016289178A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016289178-A1 |
| Application number | US-201615175821-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jun 7, 2016 |
| Priority date | Jun 10, 2013 |
| Publication date | Oct 6, 2016 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
Opening claim text (preview).
1 .- 11 . (canceled) 12 . The compound 13 .- 38 . (canceled)
Sulfinic acids; Derivatives thereof · CPC title
Ortho-condensed systems · CPC title
containing only one sulfo group · CPC title
Oxygen atom, e.g. piperidine N-oxide · CPC title
having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.